Qi Leng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Qi Leng has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Li Liu
Zhejiang Univ, Affiliated Hosp 1, Sch Med, Lib, Hangzhou 310003, Zhejiang, Peoples R China
2 shared publicationsBinyu Zhuang
Department of Dermatology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150001, China
1 shared publicationCha-Sheng Yan
Shengzhou Ganlin Town Hlth Ctr, Gen Practice Med, Shaoxing 312400, Zhejiang, Peoples R China
1 shared publicationJianling Su
Department of Rheumatology and Clinical Immunology, Guangdong Provincial People's Hospital, Guangdong Cardiovascular Institute, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China
1 shared publicationJin-Rong Li
Shengzhou Ganlin Town Hlth Ctr, Gen Practice Med, Shaoxing 312400, Zhejiang, Peoples R China
1 shared publicationLin-Fei Wu
Zhejiang Univ, Affiliated Hosp 1, Shengzhou Peoples Hosp, Gen Practice Med,Shengzhou Branch,Sch Med, Shaoxing 312400, Zhejiang, Peoples R China
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 15 January 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (1) , e71192
Research Progress of Ferroptosis in Cerebral Infarction
Purpose : To synthesize current mechanistic insights and translational progress on ferroptosis, a regulated, iron‐dependent, nonapoptotic cell death pathway in the pathophysiology and treatment of cerebral infarction (ischemic stroke), and to outline therapeutic opportunities and remaining gaps for clinical application. Method : Narrative, focused review of preclinical and translational studies (in vitro, ex vivo, and in vivo ischemia/reperfusion and middle cerebral artery occlusion models), alongside emerging biomarker, nanocarrier, and gene/RNA‐based strategies reported up to 2025. Evidence was organized across five domains: (1) redox and lipid peroxidation biology; (2) iron metabolism and ferritinophagy; (3) mitochondrial dysfunction; (4) neuroinflammation and blood–brain barrier integrity; and (5) therapeutic development and early clinical exploration. Finding : Ferroptosis in cerebral infarction is driven by glutathione depletion, glutathione peroxidase‐4 (GPX4) inactivation, and iron‐catalyzed lipid peroxidation of polyunsaturated phospholipids, with acyl‐CoA synthetase long‐chain family member‐4 (ACSL4) and lysophosphatidylcholine acyltransferase‐3 (LPCAT3) priming membranes for oxidative injury. Mitochondrial reactive oxygen species, iron–sulfur cluster instability, and cardiolipin oxidation amplify ferroptotic signaling, while ferroptosis–inflammation crosstalk (via damage‐associated molecular patterns and microglial activation) aggravates secondary injury and blood–brain barrier disruption. Candidate biomarkers (e.g., oxylipins, 8‐iso‐prostaglandin F2α, GPX4 fragments; gene pairs such as CDKN1A/JUN; NFE2L2 pathway readouts) show promise for patient stratification. Pharmacological approaches—including radical‐trapping antioxidants (ferrostatin‐1, liproxstatin‐1), iron chelation, and nuclear factor erythroid 2–related factor 2 (Nrf2) activation—consistently reduce infarct volume and improve function in animal models. Nanoparticle formulations enhance brain delivery of ferroptosis modulators, and RNA/gene‐targeted strategies (e.g., SLC7A11/GPX4/FSP1 axes; exosomal noncoding RNAs) expand the therapeutic toolkit. Clinically, iron‐modulating strategies in ischemic stroke suggest feasibility; however, dedicated, biomarker‐guided ferroptosis trials remain limited. Conclusion : Ferroptosis represents a convergent, actionable mechanism of ischemic neuronal death and secondary brain injury. Multimodal interventions that combine lipid peroxidation control, iron homeostasis, mitochondrial protection, and inflammation resolution are biologically compelling. Key next steps include: validating real‐time biomarkers for patient selection and timing; optimizing brain‐penetrant delivery systems; integrating ferroptosis modulation with reperfusion therapies; and advancing rigorously designed phase II/III trials to establish efficacy and safety in defined stroke subtypes.
- 15 January 2026
- Published by Wiley in Brain and Behavior
- Vol. 16 (1) , e71192
Top Cited PapersOpen AccessResearch Progress of Ferroptosis in Cerebral Infarction
Purpose : To synthesize current mechanistic insights and translational progress on ferroptosis, a regulated, iron‐dependent, nonapoptotic cell death pathway in the pathophysiology and treatment of cerebral infarction (ischemic stroke), and to outline therapeutic opportunities and remaining gaps for clinical application. Method : Narrative, focused review of preclinical and translational studies (in vitro, ex vivo, and in vivo ischemia/reperfusion and middle cerebral artery occlusion models), alongside emerging biomarker, nanocarrier, and gene/RNA‐based strategies reported up to 2025. Evidence was organized across five domains: (1) redox and lipid peroxidation biology; (2) iron metabolism and ferritinophagy; (3) mitochondrial dysfunction; (4) neuroinflammation and blood–brain barrier integrity; and (5) therapeutic development and early clinical exploration. Finding : Ferroptosis in cerebral infarction is driven by glutathione depletion, glutathione peroxidase‐4 (GPX4) inactivation, and iron‐catalyzed lipid peroxidation of polyunsaturated phospholipids, with acyl‐CoA synthetase long‐chain family member‐4 (ACSL4) and lysophosphatidylcholine acyltransferase‐3 (LPCAT3) priming membranes for oxidative injury. Mitochondrial reactive oxygen species, iron–sulfur cluster instability, and cardiolipin oxidation amplify ferroptotic signaling, while ferroptosis–inflammation crosstalk (via damage‐associated molecular patterns and microglial activation) aggravates secondary injury and blood–brain barrier disruption. Candidate biomarkers (e.g., oxylipins, 8‐iso‐prostaglandin F2α, GPX4 fragments; gene pairs such as CDKN1A/JUN; NFE2L2 pathway readouts) show promise for patient stratification. Pharmacological approaches—including radical‐trapping antioxidants (ferrostatin‐1, liproxstatin‐1), iron chelation, and nuclear factor erythroid 2–related factor 2 (Nrf2) activation—consistently reduce infarct volume and improve function in animal models. Nanoparticle formulations enhance brain delivery of ferroptosis modulators, and RNA/gene‐targeted strategies (e.g., SLC7A11/GPX4/FSP1 axes; exosomal noncoding RNAs) expand the therapeutic toolkit. Clinically, iron‐modulating strategies in ischemic stroke suggest feasibility; however, dedicated, biomarker‐guided ferroptosis trials remain limited. Conclusion : Ferroptosis represents a convergent, actionable mechanism of ischemic neuronal death and secondary brain injury. Multimodal interventions that combine lipid peroxidation control, iron homeostasis, mitochondrial protection, and inflammation resolution are biologically compelling. Key next steps include: validating real‐time biomarkers for patient selection and timing; optimizing brain‐penetrant delivery systems; integrating ferroptosis modulation with reperfusion therapies; and advancing rigorously designed phase II/III trials to establish efficacy and safety in defined stroke subtypes.
- 20 November 2024
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 131, 110925
Community-based smart healthcare initiative reduces carotid intima-media thickness and thrombotic markers in patients with hypertension: A prospective study
- 20 November 2024
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 131, 110925
Community-based smart healthcare initiative reduces carotid intima-media thickness and thrombotic markers in patients with hypertension: A prospective study